Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.

Saved in:
Bibliographic Details
Title: Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.
Authors: Jakacki RI; Children's Hospital of Pittsburgh, University of Pittsburgh, 4401 Penn Ave., Pittsburgh, PA, 15224, USA. regina.jakacki@astrazeneca.com.; AstraZeneca, One Medimmune Way, Gaithersburg, MD, 20878, USA. regina.jakacki@astrazeneca.com., Foley MA; Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL, 60062, USA., Horan J; Novella Clinical, 4840 Pearl E Cir # 100, Boulder, CO, 80301, USA., Wang J; Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL, 60062, USA., Kieran MW; Pediatric Neuro-Oncology, Dana-Farber Cancer Institution, Boston Children's Hospital, 450 Brookline Ave., D-3154, Boston, MA, 02215, USA., Bowers DC; Department of Pediatrics, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA., Bouffet E; The Hospital for Sick Kids, 555 University Avenue, Toronto, ON, M5G 1X8, Canada., Zacharoulis S; The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK., Gill SC; Astellas Pharma Global Development, 1 Astellas Way, Northbrook, IL, 60062, USA.
Source: Journal of neuro-oncology [J Neurooncol] 2016 Aug; Vol. 129 (1), pp. 131-8. Date of Electronic Publication: 2016 Jun 10.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1573-7373
DOI:10.1007/s11060-016-2155-4